PIK3CA and cervical cancer: This indicated that paclitaxel combined with a PI3K inhibitor could reduce the invasion and migration by the two paclitaxel-resistant cervical cancer cell lines rather than paclitaxel treatment alone (*p < 0.05; **p < 0.01; ***p < 0.01; Figure 6A,B).